PLx Pharma Inc. Reports Second Quarter 2018 Results

March 24, 2019 PDUFA Goal Date for IV Meloxicam Record CDMO Performance; 2018 Revenues of $77.3 Million Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Feb.....»»

JERUSALEM, Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31.....»»

ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board.....»»

HAIKOU CITY, China, May 15, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialt.....»»

NEW YORK and VIENNA, Austria, May 14, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics t.....»»

Gimotiâ„¢ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutic.....»»

Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights.....»»

VANCOUVER and HOUSTON, May 7, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX, TSXV:EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corpora.....»»

First Qu.....»»

Revenues of $1.7 million, up 34% compared to previous quarter Net loss .....»»

Net loss of $33.5 million for the fourth quarter of 2019, compared with net income of $58.8 million for the fourth quarter of 2018; Adjusted net .....»»

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update.....»»

Reports Q4 GAAP Earnings per Diluted Share of $1.61 versus $0.74 in Q4 2018 Reports Q4 Adjusted Earnings per Diluted Share of $1.85 versus $1.10 in Q4 2018 Defers Fiscal .....»»

Revenue from marketed dermatology products increased 85% for fourth quarter 2019 and 49% for full-year 2019 compared to 2018 NDA for IV tramadol accepted .....»»

JERUSALEM, March 13, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Com.....»»

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results.....»»

-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners -- SPARTA, New Jersey, March 13, 2020 .....»»

Fourth Quarter Highlights – 2019 vs. 2018 Revenue up 23% to $5.7 million from $4.6 million  Gross margin increased to 48.1% from 38.2%  Net income attributable to WFCF up .....»»

NEW YORK, March 4, 2020 /PRNewswire/ -- Fourth Quarter and Full Year 2019 Highlights: Gross revenues of $62.8 million for the year, up 6% versus 2018 Operating income of $17......»»

Fourth Quarter 2019 Highlights Generated $121 million or $0.43 per share of free cash flow ("FCF") in the quarter compared to $98 million or $0.34 per share of FCF for the same period in 2018, a 26 per cent increase; Advanced our Clean Energy Inves.....»»